High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Monique Terwijn, Wim L. J. van Putten, Angele Kelder, Vincent H. J. van der Velden, Rik A. Brooimans, Thomas Pabst, Johan Maertens, Nancy Boeckx, Georgine E. de Greef, Peter J. M. Valk, Frank W. M. B. Preijers, Peter C. Huijgens, Angelika M. Draeger, Urs Schanz, Mojca Jongen-Lavrecic, Bart J. Biemond, Jakob R. Passweg, Michel van Gelder, Pierre Wijermans, Carlos GrauxMario Bargetzi, Marie-Cecile Legdeur, Jurgen Kuball, Okke de Weerdt, Yves Chalandon, Urs Hess, Leo F. Verdonck, Jan W. Gratama, Yvonne J. M. Oussoren, Willemijn J. Scholten, Jennita Slomp, Alexander N. Snel, Marie-Christiane Vekemans, Bob Loewenberg, Gert Jan Ossenkoppele, Gerrit J. Schuurhuis*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)3889-3897
JournalJournal of Clinical Oncology
Volume31
Issue number31
DOIs
Publication statusPublished - 1 Nov 2013

Cite this